ルキソリチニブの徐放性投薬形態

Title:

ルキソリチニブの徐放性投薬形態

Document Type and Number:

Japanese Patent JP7225299

Kind Code:

B2

Abstract:

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.

More Like This:

JP6523566	Crystal form, production method and intermediate of dihydropyrido cyclic compound
JP2023058657	THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
JP2021006579	INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY

Inventors:

Yong Nee
Babnish Parik
Krishna Swami Yereswaram
Susan Ericsson-Bytanen
William Buoy Williams

Application Number:

JP2021069078A

Publication Date:

February 20, 2023

Filing Date:

April 15, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

INCYTE HOLDINGS CORPORATION

International Classes:

A61K31/519; A61K47/04; A61K47/12; A61K47/26; A61K47/38; A61P1/04; A61P3/02; A61P3/10; A61P5/14; A61P7/00; A61P9/00; A61P9/10; A61P11/00; A61P13/12; A61P17/00; A61P17/06; A61P19/00; A61P19/02; A61P19/10; A61P21/04; A61P25/00; A61P25/02; A61P27/02; A61P29/00; A61P31/12; A61P31/14; A61P31/18; A61P31/20; A61P31/22; A61P35/00; A61P35/02; A61P37/06; A61P43/00

Domestic Patent References:

JP2007080776A1

Foreign References:

US20110223210

Other References:

HIGHLIGHTS OF PRESCRIBING INFORMATION,2011年,pp.1-23

Attorney, Agent or Firm:

Michiko Matsutani
Yasushi Ochiai

Previous Patent: Distributed consensus method, distributed system and distributed consensus program

Next Patent: Stereoscopic visualization camera and platform